Symyoo, a leading full-service CRO with over 15 years of experience in clinical development, is participating in Bio Korea 2025.

The company brings extensive expertise conducting over 250 clinical studies across more than 30 therapeutic areas, including oncology, rare diseases, neurology, and infectious diseases. Notably, two-thirds of Symyoo’s clinical trials have been registrational studies, highlighting the organization’s regulatory proficiency.

We, Symyoo, deliver efficient and reliable trial execution for both drug and medical device studies with South Korea’s accelerated approval timelines and trusted clinical sites, combined with our proprietary SYNeRA™ CTMS digital platform.

Industry professionals interested in learning more about Symyoo’s capabilities are encouraged to visit their booth at Bio Korea 2025 or contact directly to info@symyoo.com.